174 related articles for article (PubMed ID: 32691591)
1. Design and Synthesis of a Highly Selective and
Preston A; Atkinson S; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Gray JRJ; Jones EJ; Lindon M; Michon AM; Mitchell DJ; Prinjha RK; Rianjongdee F; Rioja I; Seal J; Taylor S; Wall I; Watson RJ; Woolven J; Demont EH
J Med Chem; 2020 Sep; 63(17):9070-9092. PubMed ID: 32691591
[TBL] [Abstract][Full Text] [Related]
2. The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor.
Seal JT; Atkinson SJ; Aylott H; Bamborough P; Chung CW; Copley RCB; Gordon L; Grandi P; Gray JRJ; Harrison LA; Hayhow TG; Lindon M; Messenger C; Michon AM; Mitchell D; Preston A; Prinjha RK; Rioja I; Taylor S; Wall ID; Watson RJ; Woolven JM; Demont EH
J Med Chem; 2020 Sep; 63(17):9093-9126. PubMed ID: 32702236
[TBL] [Abstract][Full Text] [Related]
3. GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
Watson RJ; Bamborough P; Barnett H; Chung CW; Davis R; Gordon L; Grandi P; Petretich M; Phillipou A; Prinjha RK; Rioja I; Soden P; Werner T; Demont EH
J Med Chem; 2020 Sep; 63(17):9045-9069. PubMed ID: 32691589
[TBL] [Abstract][Full Text] [Related]
4. GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family.
Preston A; Atkinson SJ; Bamborough P; Chung CW; Gordon LJ; Grandi P; Gray JRJ; Harrison LA; Lewis AJ; Lugo D; Messenger C; Michon AM; Mitchell DJ; Prinjha RK; Rioja I; Seal J; Taylor S; Thesmar P; Wall ID; Watson RJ; Woolven JM; Demont EH
ACS Med Chem Lett; 2020 Aug; 11(8):1581-1587. PubMed ID: 32832027
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Series of
Harrison LA; Atkinson SJ; Bassil A; Chung CW; Grandi P; Gray JRJ; Levernier E; Lewis A; Lugo D; Messenger C; Michon AM; Mitchell DJ; Preston A; Prinjha RK; Rioja I; Seal JT; Taylor S; Wall ID; Watson RJ; Woolven JM; Demont EH
J Med Chem; 2021 Aug; 64(15):10742-10771. PubMed ID: 34232650
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 8-Methyl-pyrrolo[1,2-
Li Z; Xiao S; Yang Y; Chen C; Lu T; Chen Z; Jiang H; Chen S; Luo C; Zhou B
J Med Chem; 2020 Apr; 63(8):3956-3975. PubMed ID: 32208600
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation-induced profibrotic fibroblast responses.
Liu CS; Rioja I; Bakr A; Veldwijk MR; Sperk E; Herskind C; Weichenhan D; Prinjha RK; Plass C; Schmezer P; Popanda O
Int J Cancer; 2022 Jul; 151(2):275-286. PubMed ID: 35239184
[TBL] [Abstract][Full Text] [Related]
10. Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors.
Aylott HE; Atkinson SJ; Bamborough P; Bassil A; Chung CW; Gordon L; Grandi P; Gray JRJ; Harrison LA; Hayhow TG; Messenger C; Mitchell D; Phillipou A; Preston A; Prinjha RK; Rianjongdee F; Rioja I; Seal JT; Wall ID; Watson RJ; Woolven JM; Demont EH
J Med Chem; 2021 Mar; 64(6):3249-3281. PubMed ID: 33662213
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
12. Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
Bradley E; Fusani L; Chung CW; Craggs PD; Demont EH; Humphreys PG; Mitchell DJ; Phillipou A; Rioja I; Shah RR; Wellaway CR; Prinjha RK; Palmer DS; Kerr WJ; Reid M; Wall ID; Cookson R
J Med Chem; 2023 Dec; 66(23):15728-15749. PubMed ID: 37967462
[TBL] [Abstract][Full Text] [Related]
13. Discovery of
Sheppard GS; Wang L; Fidanze SD; Hasvold LA; Liu D; Pratt JK; Park CH; Longenecker K; Qiu W; Torrent M; Kovar PJ; Bui M; Faivre E; Huang X; Lin X; Wilcox D; Zhang L; Shen Y; Albert DH; Magoc TJ; Rajaraman G; Kati WM; McDaniel KF
J Med Chem; 2020 May; 63(10):5585-5623. PubMed ID: 32324999
[TBL] [Abstract][Full Text] [Related]
14. Computational study on the selective inhibition mechanism of MS402 to the first and second bromodomains of BRD4.
Wang Q; Li Y; Xu J; Wang Y; Shi D; Liu L; Leung EL; Yao X
Proteins; 2019 Jan; 87(1):3-11. PubMed ID: 30260047
[TBL] [Abstract][Full Text] [Related]
15. Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors.
Li Y; Shen Z; Ratia K; Zhao J; Huang F; Dubrovyskyii O; Indukuri D; Fu J; Lozano Ramos O; Thatcher GRJ; Xiong R
J Med Chem; 2024 Feb; 67(4):2712-2731. PubMed ID: 38295759
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Benzo[
Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
[TBL] [Abstract][Full Text] [Related]
17. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
[TBL] [Abstract][Full Text] [Related]
19. Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer.
Slavish PJ; Chi L; Yun MK; Tsurkan L; Martinez NE; Jonchere B; Chai SC; Connelly M; Waddell MB; Das S; Neale G; Li Z; Shadrick WR; Olsen RR; Freeman KW; Low JA; Price JE; Young BM; Bharatham N; Boyd VA; Yang J; Lee RE; Morfouace M; Roussel MF; Chen T; Savic D; Guy RK; White SW; Shelat AA; Potter PM
Cancer Res; 2020 Sep; 80(17):3507-3518. PubMed ID: 32651255
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit.
Rianjongdee F; Atkinson SJ; Chung CW; Grandi P; Gray JRJ; Kaushansky LJ; Medeiros P; Messenger C; Phillipou A; Preston A; Prinjha RK; Rioja I; Satz AL; Taylor S; Wall ID; Watson RJ; Yao G; Demont EH
J Med Chem; 2021 Aug; 64(15):10806-10833. PubMed ID: 34251219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
